News Banner

MaxQ AI Receives FDA Clearance for Accipio Ix™

FDA Clearance for Accipio Ix™ Intracranial Hemorrhage Platform

Agreement will pave the way for integration of MaxQ AI’s artificial intelligence Accipio Ix™ intracranial hemorrhage software into NeuroLogica’s medical imaging platforms in the U.S. and E.U. acute care market

Tel Aviv, Israel and Andover, MA – November 7, 2018 – MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers and physicians in acute care settings to have access to this artificial intelligence (AI) software designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of intracranial hemorrhage (ICH), commonly known as a brain bleed.


“We are very pleased to receive FDA 510(k) clearance for Accipio Ix, which we believe will be a transformative solution for medicine,” said Gene Saragnese, Chairman and CEO of MaxQ AI. “MaxQ AI’s ACCIPIO application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed.”

Earlier this year, MaxQ AI announced CE Mark approval and commercial availability in the European Union. Now, Accipio Ix is cleared for commercial sale within the United States. Accipio Ix leverages artificial intelligence technology to automatically analyze non-contrast head CT images without workflow impact to the reader, altering the original series or storing Protected Health Information (PHI). The AI-powered Accipio Ix, part of MaxQ AI’s unique ACCIPIO INSIGHT™ platform, is designed to be highly sensitive to the presence of ICH, identifying, and prioritizing patients with ICH for the treating physician. It provides a capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.

“Accipio Ix’s ability to greatly increase suspected bleed detection, improve escalation, and time to review is a game-changer. Further, our partnerships with top CT and PACS companies including GE Healthcare, Samsung Neurologica, and other organizations prior announced, make deployment and adoption of ACCIPIO straightforward,” added Saragnese. “The potential impact is massive – only one patient diverted from acute stroke to wellness in the 13,000 U.S./E.U. hospitals represent $2 billion savings in a single year and a lifetime of difference to the patient and their families.”

MaxQ AI will be demonstrating Accipio Ix – along with the full suite of ACCIPIO platform solutions – during the Radiological Society of North America (RSNA) 2018 Annual Meeting in Chicago (Booth #6161 in the North Hall).

About MaxQ AI

MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide ‘smarter care’ with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel, and Andover, MA, our team of deep learning and machine vision experts develop clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis. Working with world-class clinical and industry partners, we are raising the level of acute care in hospitals around the world to improve patient outcomes and lower costs. To learn more, please visit or follow us on LinkedIn.